Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,928 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Pressure, High Clear all
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure

NCT03714776
View directory record Official record
Conditions
Mild Hypertension
Interventions
Placebo, ISIS 757456
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
6
States / cities
Tustin, California • Port Orange, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 14, 2026, 9:51 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

NCT04365868
View directory record Official record
Conditions
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Interventions
belapectin, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Terminated Phase 4 Interventional Results available

Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension

NCT03044314
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Iloprost and nitric oxide administration
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

NCT01051960
View directory record Official record
Conditions
Systemic Sclerosis, Shortness of Breath, Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 14, 2026, 9:51 AM EDT
Completed No phase listed Observational

Hypertension and Sleep Disordered Breathing in Pediatrics

NCT00990899
View directory record Official record
Conditions
Hypertension, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
10 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension

NCT00105209
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Aspirin, clopidogrel
Drug
Lead sponsor
Kawut, Steven, MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

NCT02603809
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg, Aprocitentan 50 mg, Lisinopril 20 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
74
States / cities
Fort Payne, Alabama • Chandler, Arizona • Peoria, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 4 Interventional

Vascular Improvement With Olmesartan Medoxomil Study

NCT00772499
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure, atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting Phase 3 Interventional

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

NCT07613099
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury, Pulmonary Arterial Hypertension, Cardiovascular Diseases
Interventions
[18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
Drug · Diagnostic Test
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep and Circadian Mechanisms of Non-dipping Blood Pressure

NCT03558893
View directory record Official record
Conditions
Hypertension, Cardiovascular Risk Factor
Interventions
Forced Desynchrony
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Low Dose Aspirin Alerts in High-Risk Pregnancies

NCT05802940
View directory record Official record
Conditions
Preeclampsia, Aspirin, Clinical Decision Support Systems, Economics, Behavioral
Interventions
Electronic health record best practice alert
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
Female only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Preeclampsia: A Marker for Future Cardiovascular Risk in Women

NCT01519297
View directory record Official record
Conditions
Preeclampsia, Pregnancy Induced Hypertension
Interventions
Irbesartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring

NCT07204756
View directory record Official record
Conditions
Postpartum, Hypertension, Hypertensive Disorder of Pregnancy
Interventions
2-Week Home Monitoring, 6-Week Home Monitoring
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vitamin D for Chemoprevention

NCT00585637
View directory record Official record
Conditions
Gastrointestinal Cancers, Prostate Cancer, Hypertension
Interventions
Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years to 80 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

Innovative Approaches to Hypertension Management in High-Risk Emergency Department Populations

NCT07539597
View directory record Official record
Conditions
Asymptomatic Hypertension
Interventions
Community Health Worker engagement
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Active, not recruiting Phase 1 Interventional

Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH.

NCT07751120
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

NCT03556020
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046)
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
26
States / cities
Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators

NCT02111980
View directory record Official record
Conditions
Cardiomyopathy, Cardiac Arrhythmia, Heart Failure, Chronic Thromboembolic Pulmonary Hypertension
Interventions
RF Assure Scanning
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

Peripheral Nerve Blocks for Above-the-knee Amputations

NCT03404180
View directory record Official record
Conditions
Peripheral Vascular Diseases, Hyperglycaemia (Diabetic), Hypertension, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions
Peripheral nerve block, Intravenous Sedatives, Lateral femoral cutaneous nerve blocks, Obturator nerve blocks
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Enrolling by invitation Not applicable Interventional

Effectiveness of a Large Language Model-Based Educational Tool on Visual Field Test Reliability in Glaucoma Patients

NCT07327242
View directory record Official record
Conditions
Glaucoma, Eye Disorders, Visual Fields, Visual Field Tests
Interventions
LLM-based Education
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Military Health and Nutrition Examination Study

NCT06380322
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes, Dyslipidemias, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Fort Carson, Colorado • Hinesville, Georgia • Fort Campbell, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Endoscopic Goniotomy for Infantile Glaucoma

NCT00338533
View directory record Official record
Conditions
Glaucoma
Interventions
endoscopic goniotomy
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Week to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 14, 2026, 9:51 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome

NCT02896452
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Idiopathic Intracranial Hypertension
Interventions
Not listed
Lead sponsor
National Aeronautics and Space Administration
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 14, 2026, 9:51 AM EDT